Stocks TelegraphStocks Telegraph
Stock Ideas

BGNE Company Profile and Key Details

NASDAQ : BGNE

BeiGene

$184.71
0.9+0.49%
At Close 4:00 PM
Not Actively Trading
60.87
BESG ScoreESG Rating
ProfileKey StatsAnalyst RatingsOwnershipRatiosFinancialsDividend & splitsSentimentForecast

Price Chart

Stock Price Today

BeiGene, Ltd. (BGNE) stock surged +0.49%, trading at $184.71 on NASDAQ, up from the previous close of $183.81. The stock opened at $184.00, fluctuating between $183.91 and $187.42 in the recent session.

Stock Snapshot

183.81
Prev. Close
20.21B
Market Cap
183.91
Day Low
-22.553113553113555
P/E Ratio
-8.19
EPS (TTM)
-16.85
Cash Flow per Share
184
Open
109.41M
Number of Shares
187.42
Day High
684.52%
Free Float in %
33.99
Book Value
329.4K
Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing DateAccepted Date

Annual Report (10-k)

Filing DateAccepted Date

Stock Price History Chart

DateOpenHighLowCloseVolume
Jan 29, 2025224.61228.87224.61226.71111.11K
Jan 28, 2025228.89229.00223.51226.67210.1K
Jan 27, 2025222.99227.92221.51225.24340.51K
Jan 24, 2025217.58223.54215.46222.08346.45K
Jan 23, 2025217.35223.50215.70222.24352K
Jan 22, 2025217.37223.52214.10222.22477.08K
Jan 21, 2025214.51221.79212.99218.70521.08K
Jan 17, 2025205.35211.96205.35210.08490.05K
Jan 16, 2025201.72206.82199.02205.34293.68K
Jan 15, 2025200.00203.00196.65201.72354.63K
Jan 14, 2025191.50207.67191.50200.99734.67K
Jan 13, 2025176.00184.64174.74184.61224.93K
Jan 10, 2025179.98180.10175.92176.71271.47K
Jan 08, 2025175.00177.99172.67177.88251.74K
Jan 07, 2025176.11180.40175.00175.10432.56K
Jan 06, 2025182.00182.00179.01180.64376.04K
Jan 03, 2025183.50184.76179.05180.82189.89K
Jan 02, 2025182.50186.54180.34184.00132.21K
Dec 31, 2024184.00187.42183.91184.71331.63K
Dec 30, 2024180.08185.24179.73183.81178.91K

Contact Details

Cambridge, MA 02142

United States

https://www.beigene.com781 801 1800

About Company

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Company Information

Employees10600
Beta0.63
Sales or Revenue$2.46B
5Y Sales Change%5.588%
Fiscal Year EndsDecember
SectorHealthcare
IndustryBiotechnology

Stock Peers

REGN
-4.46-0.56%
Regeneron Pharmaceuticals, Inc.$796.55ARGX
-7.07997-0.89%
argenx SE$788.49MDGL
-42.16-7.58%
Madrigal Pharmaceuticals, Inc.$514.06UTHR
-7.6-1.55%
United Therapeutics Corporation$483.23VRTX
-5.82-1.24%
Vertex Pharmaceuticals Incorporated$463.86ALNY
-1.11-0.28%
Alnylam Pharmaceuticals, Inc.$398.29KRTX
0.09+0.03%
Karuna Therapeutics, Inc.$329.83PRAX
-5.93-2.01%
Praxis Precision Medicines, Inc.$288.45KRYS
12.5+5.02%
Krystal Biotech, Inc.$261.41SGEN
-0.16-0.07%
Seagen Inc.$228.74

Company Overview

BeiGene, Ltd. (NASDAQ:BGNE) closed at $184.71 USD, gaining $0.90 (0.49%) from the previous close of $183.81. The stock is currently mid-range between its 52-week high and low $126.97 and $248.16. With a market capitalization of about $20.21 billion, BeiGene, Ltd. is classified as a large-cap and shows lower-than-market volatility (beta ~0.63). Key stats such as the average daily volume over the past year has been around 357.76 thousand shares, in line with its 52-week average. Headquartered in Cambridge, MA, BeiGene, Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO John V. Oyler, the company employs approximately 10,600 people and listed since February 03, 2016. BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -0.92%, SMA50 -6.09%, SMA200 3.36%). The stock’s 14-day RSI is 46.17 (neutral), while the ATR of 6.24 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -25.57% below its high and over 45.48% above its low.

Valuation Metrics

BeiGene, Ltd. trades at a P/E ratio of 296.98, slightly above the S&P 500 average, with a price-to-sales ratio of 4.06 and a price-to-book ratio of 4.93 trading at moderately above to book value. The P/FCF stands at 37.11, also above market averages.

Dividend & Fair Value

BeiGene, Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.15. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

BeiGene, Ltd. generated EPS of -$8.24 over the past year. Five-year average earnings growth is 5.63%. The latest quarter delivered EPS of -$1.15. The next quarter is forecast at -$0.92. Next year's EPS is expected at $8.93. BeiGene, Ltd. earnings surprise history is a mixed track record. The quarter that ended November 12, 2024, missed forecasts by 30.68%. The prior quarter beat by -100.0%. Over the last six quarters, Apple has recorded several small beats. These include -163.61% in November 09, 2023.

Shareholding & Insider Activity

BeiGene, Ltd. has 97.68 million shares outstanding. The public float is 748.93 million shares, elevated short interest at 2.64% of float. This equals 1.38 million shares. The short ratio is 3.06 days. Institutional investors hold 58.23% of the float. Insiders own 19.43%. HHLR ADVISORS, LTD. holds 125.05 million shares, BAKER BROS. ADVISORS LP has 791.49 thousand shares and Huang Jane has 1.20 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, BeiGene generated $2.46B in revenue, or $23.55 per share. Gross margin was 81.13%, operating margin -49.12%, and net profit margin -35.86%. Returns are negative, with ROA at -15.19% and ROE at -24.93%.
On valuation metrics, BeiGene trades at a P/E of 296.98, P/S of 4.06 and P/B of 4.93. The current ratio is 2.39 and quick ratio is 2.17. Operationally, the company’s inventory turnover is 1.29 and cash conversion cycle is 142.04 days. Debt-to-equity is 0.25, supported by a cash flow-to-debt ratio of 0.77.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, BeiGene posted revenue of $2.46B, down slightly from $1.42B in the prior quarter. Gross profit was $1.99B (margin 81.13%). Operating income was - $1.21B (margin -49.1%). Net income was- $881.71M (EPS - $8.45).
The company ended the quarter with $3.19B in cash and short-term investments, a total debt of $930.19M, and net debt of - $2.25B. Total assets were $5.81B, with equity of $3.54B. Financials further reflected weakness, with operating cash flow of - $1.16B, free cash flow of - $1.74B, and capital expenditures of - $581.26M.

Frequently Asked Questions

What is the current BeiGene, Ltd. (BGNE) stock price?
BeiGene, Ltd. (NASDAQ: BGNE) stock price is $184.71 in the last trading session. During the trading session, BGNE stock reached the peak price of $187.42 while $183.91 was the lowest point it dropped to. The percentage change in BGNE stock occurred in the recent session was 0.49% while the dollar amount for the price change in BGNE stock was $0.90.
BGNE's industry and sector of operation?
The NASDAQ listed BGNE is part of Biotechnology industry that operates in the broader Healthcare sector. BeiGene, Ltd. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of BGNE?
Ms. Stacey Jurchison
Executive Director of Corporation Affairs
Dr. Yan Qi
Senior Vice President & Head of Public Affairs - Greater China
Mr. Wang Lai
Global Head of R&D
Mr. Graham Hardiman
Global Head of HR
Dr. Xiaobin Wu Ph.D.
Pres & Chief Operating Officer
Dr. Xiaodong Wang Ph.D.
Co- Chairman of Scientific Advisory Board & Non-Executive Director Co-Founder
Ms. Julia Wang
Chief Financial Officer & Principal Accounting Officer
Mr. Daniel Maller
Vice President of Fin. & Accounting
Mr. John V. Oyler
Co-Founder, Executive Chairman & Chief Executive Officer
Ms. Liza Heapes
Head of Investor Relations
Mr. Chan Lee
Gen. Counsel & Senior Vice President
Ms. Diana Lee Francis
Vice President and Global Head of Quality & Regulatory Compliance
Ms. Mi Zhou
Senior Director of Investor Relations
Dr. Mark Lanasa
Senior Vice President & Chief Medical Officer for Solid Tumors
Mr. Jason W. Radford
Senior Vice President of Strategy & Corporation Devel.
How BGNE did perform over past 52-week?
BGNE's closing price is 45.48% higher than its 52-week low of $126.97 where as its distance from 52-week high of $248.16 is -25.57%.
How many employees does BGNE have?
Number of BGNE employees currently stands at 10,600.
Link for BGNE official website?
Official Website of BGNE is: https://www.beigene.com
How do I contact BGNE?
BGNE could be contacted at phone 781 801 1800 and can also be accessed through its website. BGNE operates from 55 Cambridge Parkway, Cambridge, MA 02142, United States.
How many shares of BGNE are traded daily?
BGNE stock volume for the day was 329.4K shares. The average number of BGNE shares traded daily for last 3 months was 357.77K.
What is the market cap of BGNE currently?
The market value of BGNE currently stands at $20.21B with its latest stock price at $184.71 and 109.41M of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

HomeAboutMeet The TeamContact UsPrivacy PolicyNewsletter

Useful Links

ScreenerMarket DataInsider TransactionsUpgrades & Downgrades52 Week Highs & LowsUnusual VolumeDividend CalendarEarnings CalendarStocks Watchlist
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph